标题
Axitinib plasma pharmacokinetics and ethnic differences
作者
关键词
Asian, Axitinib, Caucasian, Ethnic Factor, Pharmacokinetics
出版物
INVESTIGATIONAL NEW DRUGS
Volume 33, Issue 2, Pages 521-532
出版商
Springer Nature
发表日期
2015-02-07
DOI
10.1007/s10637-015-0214-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
- (2014) Se-Hoon Lee et al. Asia-Pacific Journal of Clinical Oncology
- Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
- (2014) Y Wang et al. BRITISH JOURNAL OF CANCER
- Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
- (2014) Masatoshi Eto et al. CANCER SCIENCE
- Population pharmacokinetic analysis of axitinib in healthy volunteers
- (2013) May Garrett et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacology of Axitinib
- (2013) Ying Chen et al. CLINICAL PHARMACOKINETICS
- Axitinib for the treatment of advanced renal cell carcinoma
- (2013) Hideyuki Akaza et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
- (2013) T. Ueda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers
- (2012) Yazdi K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic evaluation of axitinib
- (2012) Brian Patson et al. Expert Opinion on Drug Metabolism & Toxicology
- Concise Drug Review: Pazopanib and Axitinib
- (2012) R. M. J. M. van Geel et al. ONCOLOGIST
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development
- (2011) Kouichi Kurose et al. Drug Metabolism and Pharmacokinetics
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
- (2011) Yoshihiko Tomita et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
- (2011) Meghan Brennan et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers
- (2011) Y. Chen et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
- (2011) Yutaka Fujiwara et al. INVESTIGATIONAL NEW DRUGS
- Clinical Outcome and Prognostic Factors of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma in General Clinical Practice
- (2011) G. Tanigawa et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
- (2010) Yazdi K. Pithavala et al. INVESTIGATIONAL NEW DRUGS
- Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
- (2010) Michael A. Tortorici et al. INVESTIGATIONAL NEW DRUGS
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
- (2010) Y. Tomita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
- (2010) C. Yoo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
- (2009) Hailiang Zhang et al. BMC CANCER
- Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
- (2009) Y. K. Pithavala et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients
- (2009) Toru Mukohara et al. CANCER SCIENCE
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
- (2009) B. E. Houk et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Pazopanib in Patients with Advanced Cancer
- (2009) H. I. Hurwitz et al. CLINICAL CANCER RESEARCH
- Pharmacogenetics of Phase I and Phase II Drug Metabolism
- (2009) Severine Crettol et al. CURRENT PHARMACEUTICAL DESIGN
- A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety
- (2009) H. Uemura et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
- (2009) Min Hee Hong et al. Cancer Research and Treatment
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started